Zobrazeno 1 - 10
of 43
pro vyhledávání: '"Lisa L Brennan"'
Autor:
Eva Guinan, David E Avigan, Robert J Soiffer, Nancy J Bunin, Lisa L Brennan, Ilana Bergelson, Spencer Brightman, Al Ozonoff, Patrick J Scannon, Ofer Levy
Publikováno v:
F1000Research, Vol 4 (2015)
Bacterial infection and inflammation contribute significantly to the morbidity and mortality of myeloablative allogeneic hematopoietic cell transplantation (HCT). Endotoxin, a component of the outer membrane of Gram-negative bacteria, is a potent inf
Externí odkaz:
https://doaj.org/article/38a21c9830564e2d829e4fd9bc79c3cd
Autor:
Urvashi Bhatia, Katsuyoshi Shimozawa, Sofia Sousa, Laura Contreras-Ruiz, Kerry C Crisalli, Ruan Zhang, Lisa L. Brennan, Eva C. Guinan, James F. Markmann, Laurence A. Turka
Publikováno v:
Am J Transplant
The potential of adoptive cell therapy with regulatory T cells (Tregs) to promote transplant tolerance is under active exploration. However, the impact of specific transplant settings and protocols on Treg manufacturing is not well-delineated. Here,
Autor:
Eva C. Guinan, Lee M. Nadler, Richard E. Champlin, Peter F. Thall, Laurence J. Cooper, Marcos de Lima, Thomas R. Spitzer, Bimalangshu R. Dey, Ami J. Shah, Neena Kapoor, Christopher R. Cogle, John R. Wingard, Lisa L. Brennan, Jeff K. Davies
Purpose: Allogeneic hematopoietic stem-cell transplantation (HSCT) is a curative treatment for many hematologic cancers. Use of haploidentical (mismatched) donors increases HSCT availability but is limited by severe graft-versus-host disease (GvHD) a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4657df4073dbc61e5035bb4eacd58ef8
https://doi.org/10.1158/1078-0432.c.6527625
https://doi.org/10.1158/1078-0432.c.6527625
Autor:
Eva C. Guinan, Lee M. Nadler, Richard E. Champlin, Peter F. Thall, Laurence J. Cooper, Marcos de Lima, Thomas R. Spitzer, Bimalangshu R. Dey, Ami J. Shah, Neena Kapoor, Christopher R. Cogle, John R. Wingard, Lisa L. Brennan, Jeff K. Davies
Table S1 Patients, donors, HLA-mismatches and conditioning; Table S2 Cell doses in stem cell transplant, engraftment and chimerism; Table S3 ADLI dose and timing and allostimulator source; Table S4 Patient outcomes; Figure S1 Schema for clinical stud
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a511c5315fc2fb51fb247093d838fa2
https://doi.org/10.1158/1078-0432.22470588
https://doi.org/10.1158/1078-0432.22470588
Autor:
Eva C. Guinan, John R. Wingard, Christopher R. Cogle, Peter F. Thall, Laurence J.N. Cooper, Bimalangshu R. Dey, Lisa L. Brennan, Neena Kapoor, Ami J. Shah, Thomas R. Spitzer, Richard E. Champlin, Jeff K. Davies, Lee M. Nadler, Marcos de Lima
Publikováno v:
Clinical Cancer Research. 24:4098-4109
Purpose: Allogeneic hematopoietic stem-cell transplantation (HSCT) is a curative treatment for many hematologic cancers. Use of haploidentical (mismatched) donors increases HSCT availability but is limited by severe graft-versus-host disease (GvHD) a
Autor:
Karen Francoeur, Matthew S. Davids, Jacob D. Soumerai, Alexandra Savell, Jennifer R. Brown, Jessica Lowney, Austin I. Kim, Zixu Wang, David C. Fisher, Josie Montegaard, Allan Louie Cruz, Lisa L. Brennan, Sigrid Berg, Svitlana Tyekucheva, Jennifer L. Crombie, Jon E. Arnason
Publikováno v:
Blood. 136:46-47
Introduction: The MURANO study demonstrated that venetoclax (VEN) plus rituximab is an effective regimen for pts with relapsed/refractory (R/R) CLL, but included 2 years of treatment and an infusional component (Seymour et al., NEJM, 2018). Duvelisib
Autor:
J. Oppatt, James F. Markmann, Kenneth J. Janec, H. Yuan, Lisa L. Brennan, W. H. Wylie, R. H. Kelner, Laurence A. Turka, Eva C. Guinan, G. A. Cole
Publikováno v:
American Journal of Transplantation. 16:2187-2195
Short-term outcomes of kidney transplantation have improved dramatically, but chronic rejection and regimen-related toxicity continue to compromise overall patient outcomes. Development of regulatory T cells (Tregs) as a means to decrease allorespons
Autor:
Eugenie E. Suter, Maria A. Mansilla, Christy J. Mancuso, Ofer Levy, Leslie A. Kalish, Jerrold Weiss, Christine D. Palmer, Ralf R. Schumann, Liat Stoler-Barak, Lisa L. Brennan, Jeffrey C. Murray, David P Huhtelin, Eva C. Guinan, Leighanne C. Gallington
Publikováno v:
Innate Immunity. 20:697-711
Hematopoietic cell transplant (HCT) is a life-saving therapy for many malignant and non-malignant bone marrow diseases. Associated morbidities are often due to transplant-related toxicities and infections, exacerbated by regimen-induced immune suppre
Publikováno v:
Pediatric Hematology and Oncology. 30:116-130
Chemotherapy dosing in hematopoietic cell therapy (HCT) conditioning regimens is based on patient weight. We hypothesized that potential underdosing or overdosing of patients with significant deviation of weight from normal might alter HCT outcomes,
Publikováno v:
Blood. 112:2232-2241
We report the outcomes of 24 patients with high-risk hematologic malignancies or bone marrow failure (BMF) who received haploidentical bone marrow transplantation (BMT) after ex vivo induction of alloantigen-specific anergy in donor T cells by allost